Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 2, Pages 292-299
Publisher
Springer Nature
Online
2014-06-12
DOI
10.1038/bjc.2014.287
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- p16INK4a Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors
- (2015) Stuart J. Gallagher et al. NEOPLASIA
- The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
- (2013) H. Ekedahl et al. BRITISH JOURNAL OF DERMATOLOGY
- Clinical characteristics and outcomes with specificBRAFandNRASmutations in patients with metastatic melanoma
- (2013) Amanda D. Bucheit et al. CANCER
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Clinical Significance of BRAF Mutation in Thyroid Papillary Cancer
- (2013) Ignacio J. Fernandez et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Prevalence of BRAF and NRAS mutations in fast-growing melanomas
- (2013) Eduardo Nagore et al. Pigment Cell & Melanoma Research
- Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
- (2012) Stéphanie Moreau et al. ANNALS OF SURGICAL ONCOLOGY
- Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma
- (2012) Rajmohan Murali et al. CANCER
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- TheBRAFV600EMutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
- (2012) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
- (2012) Graham J. Mann et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region
- (2012) Benhur Amanuel et al. PATHOLOGY
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence
- (2012) Jason D. Prescott et al. SURGERY
- First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
- (2011) R. von Moos et al. ANNALS OF ONCOLOGY
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More